The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis-Reference-Cited by-同舟云学术

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

Published:2019-03-10 Issue:3 Volume:70 Page:788-801
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Trauner Michael¹,Gulamhusein Aliya²,Hameed Bilal³,Caldwell Stephen⁴,Shiffman Mitchell L.⁵,Landis Charles⁶,Eksteen Bertus⁷,Agarwal Kosh⁸,Muir Andrew⁹,Rushbrook Simon¹⁰,Lu Xiaomin¹¹,Xu Jun¹¹,Chuang Jen‐Chieh¹¹,Billin Andrew N.¹¹,Li Georgia¹¹,Chung Chuhan¹¹,Subramanian G. Mani¹¹,Myers Robert P.¹¹,Bowlus Christopher L.¹²,Kowdley Kris V.¹³

Affiliation:

1. Medical University of Vienna Vienna Austria

2. University of Toronto Toronto ON Canada

3. University of California San Francisco School of Medicine San Francisco CA

4. University of Virginia Charlottesville VA

5. Bon Secours Liver Institute Richmond VA

6. University of Washington School of Medicine Seattle WA

7. Aspen Woods Clinic Calgary AB Canada

8. King’s College London UK

9. Duke University School of Medicine Durham NC

10. Norfolk and Norwich University Hospital Norfolk UK

11. Gilead Sciences, Inc. Foster City CA